Recently, alternative approach using radiolabeled anti-EGFR antibodies has shown precise quantification of target expression as an immuno-positron emission tomography (PET) agent and enhanced therapeutic efficacy as a radioimmunotherapeutic agent compared to immunotherapy in preclinical HNSCC xenograft models [19, 20]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.